# A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

> **NCT06474455** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SHR-9839 for Injection
- **DRUG:** SHR-A1921 for Injection
- **DRUG:** SHR-A2009 for Injection
- **DRUG:** Almonertinib Mesilate Tablets
- **DRUG:** Pemetrexed Disodium for Injection
- **DRUG:** Carboplatin for injection
- **DRUG:** Paclitaxel injection
- **DRUG:** SHR-1316 Injection
- **DRUG:** SHR-9839 for Injection (sc)

## Key facts

- **NCT ID:** NCT06474455
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-02
- **Primary completion:** 2029-06
- **Final completion:** 2029-12
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06474455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06474455, "A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-08 from https://api.morvs.ai/clinical/NCT06474455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*